Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
AJR Am J Roentgenol. 2017 Aug;209(2):277-288. doi: 10.2214/AJR.17.18264. Epub 2017 May 2. Jadvar H1.
OBJECTIVE: This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field.
CONCLUSION: TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.